Short Interest in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Expands By 8.2%

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 3,840,000 shares, a growth of 8.2% from the December 15th total of 3,550,000 shares. Based on an average daily trading volume, of 463,300 shares, the short-interest ratio is presently 8.3 days.

Institutional Investors Weigh In On Aldeyra Therapeutics

Large investors have recently modified their holdings of the business. Perceptive Advisors LLC boosted its stake in Aldeyra Therapeutics by 7.9% in the 2nd quarter. Perceptive Advisors LLC now owns 9,275,851 shares of the biotechnology company’s stock worth $30,703,000 after purchasing an additional 682,265 shares in the last quarter. State Street Corp raised its holdings in shares of Aldeyra Therapeutics by 1.7% in the third quarter. State Street Corp now owns 973,908 shares of the biotechnology company’s stock worth $5,249,000 after buying an additional 16,188 shares during the last quarter. Federated Hermes Inc. acquired a new stake in shares of Aldeyra Therapeutics during the second quarter worth $1,758,000. Jacobs Levy Equity Management Inc. grew its holdings in shares of Aldeyra Therapeutics by 163.4% during the third quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company’s stock valued at $2,571,000 after buying an additional 295,864 shares during the last quarter. Finally, International Assets Investment Management LLC increased its position in shares of Aldeyra Therapeutics by 397.0% in the 3rd quarter. International Assets Investment Management LLC now owns 287,287 shares of the biotechnology company’s stock valued at $15,480,000 after acquiring an additional 229,487 shares during the period. Hedge funds and other institutional investors own 59.71% of the company’s stock.

Aldeyra Therapeutics Price Performance

Shares of ALDX opened at $4.84 on Monday. The company has a 50 day moving average of $4.94 and a two-hundred day moving average of $4.98. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.80 and a current ratio of 6.80. Aldeyra Therapeutics has a twelve month low of $2.71 and a twelve month high of $6.55.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.25). Equities analysts predict that Aldeyra Therapeutics will post -0.92 EPS for the current fiscal year.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.